Cargando…

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

The most frequent genetic alterations of the TP53 gene in human cancer were reported. TP53 mutation gains new function as a target of genetic instability, which is associated with increased tumor progression and poor survival rate in patients. In this study, more than three hundred colorectal cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Nannan, Jiang, Xinxiu, Guo, Leiming, Zhang, Chuchu, Jiang, Meimei, Sun, Zhuoran, Zhang, Yizheng, Mi, Wunan, Li, Jiehan, Fu, Yang, Wang, Feng, Zhang, Lingling, Zhang, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990467/
https://www.ncbi.nlm.nih.gov/pubmed/35414774
http://dx.doi.org/10.7150/ijbs.67200
_version_ 1784683380024016896
author Liu, Nannan
Jiang, Xinxiu
Guo, Leiming
Zhang, Chuchu
Jiang, Meimei
Sun, Zhuoran
Zhang, Yizheng
Mi, Wunan
Li, Jiehan
Fu, Yang
Wang, Feng
Zhang, Lingling
Zhang, Yingjie
author_facet Liu, Nannan
Jiang, Xinxiu
Guo, Leiming
Zhang, Chuchu
Jiang, Meimei
Sun, Zhuoran
Zhang, Yizheng
Mi, Wunan
Li, Jiehan
Fu, Yang
Wang, Feng
Zhang, Lingling
Zhang, Yingjie
author_sort Liu, Nannan
collection PubMed
description The most frequent genetic alterations of the TP53 gene in human cancer were reported. TP53 mutation gains new function as a target of genetic instability, which is associated with increased tumor progression and poor survival rate in patients. In this study, more than three hundred colorectal cancer patients' samples were firstly analyzed, and the results showed that patients with mutant p53 had higher levels of AKT phosphorylation and PD-L1 expression, which were next verified both in cell lines in vitro and patients' samples in vivo. Further studies demonstrated that the hotspot of mutant p53 directly binds to the promoter of PHLPP2 to inhibit its transcription, and resulting in down-regulating its protein expressional level. Subsequently, AKT was released and activated, promoting tumor proliferation and metastasis. In parallel, 4EBP1/eIF4E was identified as downstream executors of AKT to enhance the translational level of PD-L1, which decreased the activation of T cells. Besides, inhibiting AKT/mTOR pathway significantly suppressed PD-L1 expression, tumor growth, and immune escape in p53 mutated cells. In conclusion, mutant p53 achieved its Gain-of-Function by transcriptionally inhibiting PHLPP2 and activating AKT, which suppresses immune response and advances tumor growth. Thus, this study provides an excellent basis for a further understanding of the clinical treatment of neoplastic diseases for patients with mutant p53, with an emphasis on immunotherapy.
format Online
Article
Text
id pubmed-8990467
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-89904672022-04-11 Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway Liu, Nannan Jiang, Xinxiu Guo, Leiming Zhang, Chuchu Jiang, Meimei Sun, Zhuoran Zhang, Yizheng Mi, Wunan Li, Jiehan Fu, Yang Wang, Feng Zhang, Lingling Zhang, Yingjie Int J Biol Sci Research Paper The most frequent genetic alterations of the TP53 gene in human cancer were reported. TP53 mutation gains new function as a target of genetic instability, which is associated with increased tumor progression and poor survival rate in patients. In this study, more than three hundred colorectal cancer patients' samples were firstly analyzed, and the results showed that patients with mutant p53 had higher levels of AKT phosphorylation and PD-L1 expression, which were next verified both in cell lines in vitro and patients' samples in vivo. Further studies demonstrated that the hotspot of mutant p53 directly binds to the promoter of PHLPP2 to inhibit its transcription, and resulting in down-regulating its protein expressional level. Subsequently, AKT was released and activated, promoting tumor proliferation and metastasis. In parallel, 4EBP1/eIF4E was identified as downstream executors of AKT to enhance the translational level of PD-L1, which decreased the activation of T cells. Besides, inhibiting AKT/mTOR pathway significantly suppressed PD-L1 expression, tumor growth, and immune escape in p53 mutated cells. In conclusion, mutant p53 achieved its Gain-of-Function by transcriptionally inhibiting PHLPP2 and activating AKT, which suppresses immune response and advances tumor growth. Thus, this study provides an excellent basis for a further understanding of the clinical treatment of neoplastic diseases for patients with mutant p53, with an emphasis on immunotherapy. Ivyspring International Publisher 2022-03-14 /pmc/articles/PMC8990467/ /pubmed/35414774 http://dx.doi.org/10.7150/ijbs.67200 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Liu, Nannan
Jiang, Xinxiu
Guo, Leiming
Zhang, Chuchu
Jiang, Meimei
Sun, Zhuoran
Zhang, Yizheng
Mi, Wunan
Li, Jiehan
Fu, Yang
Wang, Feng
Zhang, Lingling
Zhang, Yingjie
Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title_full Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title_fullStr Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title_full_unstemmed Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title_short Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
title_sort mutant p53 achieved gain-of-function by promoting tumor growth and immune escape through phlpp2/akt/pd-l1 pathway
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990467/
https://www.ncbi.nlm.nih.gov/pubmed/35414774
http://dx.doi.org/10.7150/ijbs.67200
work_keys_str_mv AT liunannan mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT jiangxinxiu mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT guoleiming mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT zhangchuchu mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT jiangmeimei mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT sunzhuoran mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT zhangyizheng mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT miwunan mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT lijiehan mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT fuyang mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT wangfeng mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT zhanglingling mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway
AT zhangyingjie mutantp53achievedgainoffunctionbypromotingtumorgrowthandimmuneescapethroughphlpp2aktpdl1pathway